High prevalence of ST5-SCCmec II-t311 clone of methicillin-resistant Staphylococcus aureus isolated from bloodstream infections in East China.

Publisher: BioMed Central Country of Publication: England NLM ID: 100966981 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2180 (Electronic) Linking ISSN: 14712180 NLM ISO Abbreviation: BMC Microbiol Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Methicillin-Resistant Staphylococcus aureus*/genetics ; Staphylococcal Infections*/drug therapy ; Sepsis*; Staphylococcus aureus/genetics ; Multilocus Sequence Typing/methods ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; China/epidemiology ; Humans ; Prevalence ; Chromosomes ; Microbial Sensitivity Tests

Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is a challenging global health threat, resulting in significant morbidity and mortality worldwide. This study aims to determine the molecular characteristics and antimicrobial susceptibility of 263 MRSA isolates in Zhejiang Province, east China.
Methods: From 2014 to 2019, a total of 263 MRSA isolates from bloodstream infections (BSIs) were collected from 6 hospitals in 4 cities in Zhejiang province, east China. Antimicrobial susceptibility tests were conducted according to the guidelines set forth by the Clinical and Laboratory Standards Institute (CLSI). To characterize and analyze these isolates, multilocus sequence typing (MLST), staphylococcal cassette chromosome mec (SCCmec) typing, staphylococcal protein A (spa) typing and virulence genes gene profiles were performed.
Results: The most predominant clone was ST5-SCCmec II-t311, which accounted for 41.8% (110/263), followed by ST59 (44/263, 16.7%). Compared with non-ST5-II-t311 isolates, ST5-II-t311 isolates were more resistant to erythromycin, tetracycline, levofloxacin, moxifloxacin, and ciprofloxacin, but more susceptible to clindamycin. Moreover, the rates of multidrug resistance were higher in ST5-II-t311 isolates compared to the non-ST5-II-t311 isolates. In comparison to the non-ST5-II-t311 isolates, ST5-II-t311 isolates showed no significant difference in virulence genes detected.
Conclusions: MRSA ST5-II-t311 clone has become the most predominant clone in Zhejiang Province, east China and has higher rates of multidrug resistance than other isolates, that should be kept in mind when treating BSI. Moreover, MRSA ST59 clone shows an upward trend and has begun to spread into hospitals. Our findings highlight the importance of epidemiological studies of S. aureus carriage in the eastern region.
(© 2024. The Author(s).)

Appl Environ Microbiol. 2004 Nov;70(11):6931-5. (PMID: 15528567)
N Engl J Med. 1998 Dec 31;339(27):2026-7. (PMID: 9882209)
China CDC Wkly. 2021 Nov 19;3(47):1005-1013. (PMID: 34888116)
JAMA. 1998 Feb 25;279(8):593-8. (PMID: 9486753)
Int J Infect Dis. 2018 Jun;71:107-112. (PMID: 29698703)
Clin Microbiol Rev. 2015 Jul;28(3):603-61. (PMID: 26016486)
Emerg Microbes Infect. 2021 Dec;10(1):1052-1064. (PMID: 33823746)
J Am Acad Dermatol. 2007 Jan;56(1):1-16; quiz 17-20. (PMID: 17190619)
Clin Microbiol Rev. 2010 Jul;23(3):616-87. (PMID: 20610826)
Clin Microbiol Rev. 2018 Sep 12;31(4):. (PMID: 30209034)
Emerg Microbes Infect. 2022 Dec;11(1):532-542. (PMID: 35060838)
Biol Pharm Bull. 2016;39(7):1195-200. (PMID: 27374293)
J Clin Microbiol. 2015 Aug;53(8):2486-91. (PMID: 26019202)
Clin Infect Dis. 1999 Nov;29(5):1128-32. (PMID: 10524952)
Clin Microbiol Infect. 2010 Dec;16(12):1721-8. (PMID: 20825434)
J Clin Microbiol. 2000 Mar;38(3):1008-15. (PMID: 10698988)
Clin Microbiol Infect. 2022 Jan;28(1):85-92. (PMID: 34022399)
Microbiol Spectr. 2022 Jun 29;10(3):e0020122. (PMID: 35638778)
Clin Infect Dis. 2006 Mar 1;42(5):647-56. (PMID: 16447110)
Clin Infect Dis. 2018 Nov 13;67(suppl_2):S241-S248. (PMID: 30423051)
Clin Microbiol Infect. 2007 Oct;13(10):971-9. (PMID: 17697003)
J Clin Microbiol. 2004 Feb;42(2):792-9. (PMID: 14766855)
J Clin Microbiol. 2013 Nov;51(11):3638-44. (PMID: 23985906)
Emerg Microbes Infect. 2021 Dec;10(1):109-122. (PMID: 33355507)
J Antimicrob Chemother. 2022 Jul 28;77(8):2130-2141. (PMID: 35639590)
Antimicrob Agents Chemother. 2019 Mar 27;63(4):. (PMID: 30718251)
J Clin Microbiol. 2021 Nov 18;59(12):e0021321. (PMID: 34550809)
J Clin Microbiol. 2015 Jan;53(1):67-72. (PMID: 25339405)
Front Microbiol. 2018 Jun 06;9:1211. (PMID: 29928269)
Nat Rev Microbiol. 2019 Apr;17(4):203-218. (PMID: 30737488)
J Antimicrob Chemother. 2020 May 1;75(5):1071-1086. (PMID: 32016348)
J Clin Microbiol. 2005 Oct;43(10):5026-33. (PMID: 16207957)
mBio. 2016 May 05;7(3):. (PMID: 27150362)
PLoS One. 2011 Apr 06;6(4):e17936. (PMID: 21494333)
Antimicrob Resist Infect Control. 2019 May 30;8:90. (PMID: 31164979)
Clin Infect Dis. 2019 Feb 1;68(4):545-553. (PMID: 30107401)
Antimicrob Agents Chemother. 2007 Jan;51(1):264-74. (PMID: 17043114)
Microb Drug Resist. 2018 Apr;24(3):283-289. (PMID: 28799881)
J Clin Microbiol. 2002 Mar;40(3):857-62. (PMID: 11880405)
Genome Med. 2021 Oct 28;13(1):171. (PMID: 34711267)
Med J Aust. 2001 Sep 3;175(5):264-7. (PMID: 11587259)
Ugeskr Laeger. 1961 Mar 17;123:384-6. (PMID: 13697147)
Clin Infect Dis. 2014 Sep 15;59(6):798-807. (PMID: 24879783)

Keywords: Antimicrobial susceptibility; Bloodstream infections (BSIs); Methicillin-resistant staphylococcus aureus (MRSA); ST5-SCCmec II-t311; Virulence genes

0 (Anti-Bacterial Agents)

Date Created: 20240316 Date Completed: 20240318 Latest Revision: 20240319

20260130

PMC10943896

10.1186/s12866-024-03232-5

38491414